Ranjeet Ajmani: Southeast Asia – 25% of The Global Population Contributes Less than 2% of The Global Plasma Supply
Ranjeet Ajmani, Chief Executive Officer- Asia at Aegros, shared on LinkedIn:
”It will be an honor to share experiences and insights at the Business Forum (October, 16, 2025) of the Plasma Protein Therapeutics Association (PPTA), Virginia, USA
Southeast Asia (SEA), home to over 2 billion people—about 25% of the global population—contributes less than 2% of the global plasma supply.
This disparity is clearly reflected in patient care, particularly in the availability, accessibility, and affordability of Plasma-Derived Medicinal Products (PDMPs).
The situation is further exacerbated by limited public healthcare expenditure, inadequate health policies, and regulatory challenges.
As a result, a vast majority of patients in developing countries remain undiagnosed.
Many live with serious, yet treatable, conditions—often in silence, suffering without support, and sadly passing away without ever receiving the care they need.
These stories are not just statistics—they are deeply human, and often heart-wrenching.
We must ask ourselves: Can we do more for our fellow citizens?
The answer must be yes.
By fostering collaboration across governments, regulators, industry, and patient advocacy groups, and by reimagining policies and infrastructure, we can build a more equitable future—one in which no one is left behind simply because of where they were born.”
Stay updated with Hemostasis Today.
-
Oct 17, 2025, 08:37Salome Mekhuzla Invites You to Join WHO Essential Medicines List 2025 Updates Webinar on Hemophilia and VWD
-
Oct 17, 2025, 08:36Plasma Protein Forum 2025: From Anti-D Plasma and Blood Supply Incentives to the Future of AI
-
Oct 17, 2025, 08:33Hossam El Benawi to Present Latest Mayo Clinic Insights on Left Ventricular Thrombus at AHA 2026
-
Oct 17, 2025, 08:32Brian O Mahony Invites You to Irish Haemophilia Society Webinar Series
-
Oct 17, 2025, 08:30Thomas Reiser Invites You to Take A Survey on AI and Machine Learning From ISTH
-
Oct 17, 2025, 09:00Shreya Agarwal: We Describe Patients With PLG Mutations Who Experienced Recurrent TMA
-
Oct 17, 2025, 08:41Review of Community-Based Stroke Rehabilitation in LMICs from Dominique Cadilhac's Team
-
Oct 16, 2025, 04:43Michael Makris Invites You to The Research Recap on FEIBA Use in Patients on Emicizumab
-
Oct 16, 2025, 04:41Suhasini Sil on Impact of AMBM Red Cell Transfusions in Improving Transfusion Outcomes
-
Oct 16, 2025, 04:37Hinde El Otmani's Team Explores Plasmin-Mediated Proteolysis of von Willebrand Factor in Acutely Ill Patients
-
Oct 14, 2025, 05:26Ryan C. Heniford: Every Thrombus Prevented Is a Patient Protected
-
Oct 13, 2025, 04:48Archil Jaliashvili showcases how BHOC builds on Hemopure’s success to revolutionize surgery and care
-
Oct 13, 2025, 02:46Flora Peyvandi: First Proposed Blood Test for Chronic Fatigue Syndrome - What Scientists Think
-
Oct 13, 2025, 02:44Silvio Maresca: Honored to be part of this international research project - ThrombUS+
-
Oct 10, 2025, 12:25Robert Lewis: T Cells Are Wonderful - But They Can't Do Everything
-
Oct 17, 2025, 08:52Erica Sparkenbaugh: Shout Out to My Doctoral Student Kylie Hutchison for Her Outstanding Oral Presentation
-
Oct 17, 2025, 08:45Shamee Shastry Shares Lean and Six Sigma in Transfusion Medicine Training Program's Success
-
Oct 16, 2025, 04:44Giles Platford Discusses Strengthening the Plasma Ecosystem for Patients Worldwide at PPF2025
-
Oct 16, 2025, 04:27Ranjeet Ajmani: Southeast Asia - 25% of The Global Population Contributes Less than 2% of The Global Plasma Supply
-
Oct 15, 2025, 05:59Courtney Lawrence: I've Got A Place at American Red Cross for You!